Tech for Mental Healthcare: New Opportunities
It’s estimated that over one billion people globally have a mental, neurodevelopment or substance use disorder (IHME, 2017). Is technology leading the charge toward a mental health revolution? And where will we see opportunities for growth and investment?
There are signs that tech will be the next big battleground for the pharmaceutical industry. “Pharmaceutical companies are now getting interested in tech. They’re seeing it as another arm of their work,” Wykes observed. “Given the general lack of evidence of drugs and the negative consequences we’ve had of giving out adult drugs to children, [the young person’s field] is a space pharmaceutical companies are likely to start getting into.” Half of all mental illness begins by the age of 14, but most cases go undetected and untreated (WHO, 2018).
There are many ways in which tech could help support people with mental health issues. “In stepped care, you might want to introduce some form of app to help people self-manage before they come into formal health services,” Wykes explained. “But you could use the same kind of app as people come out of mental health services as well, to help with their recovery and to maintain their functioning.”
King’s College London is currently conducting RADAR-CNS – a new collaborative research programme that will explore the potential of wearable devices to help prevent and treat depression, multiple sclerosis and epilepsy. “In the study, we’re using tech to see if we can predict problems in mental health – in particular, predicting whether people with depression will have a relapse,” said Wykes. “That way, we can get in quick and provide them with treatment. And we know that faster treatment means that you’re going to have a faster recovery.”
The insurance industry also stands to benefit from embracing tech-fuelled treatments. Blended care – with a tech intervention, plus formalised clinical care – “may be a cheaper way of providing services” for insurers, Wykes noted. She suggested that insurers “pay for randomised controlled trials to find the benefit [of the technologies], so they know which ones to recommend”.